Locally Advanced Cervical Carcinoma, Uterine Cervical Neoplasms
Conditions
Keywords
Non-randomized phase-II trial, Primary chemoradiotherapy, Proton therapy, Organ sparing therapy
Brief summary
This prospective, multicenter, nonrandomized phase-II-trial investigates in clinical practice the differences between intensity modulated proton therapy (IMPT) and standard intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) in the effects on dose-volume parameters and treatment-related morbidity for women with locally advanced cervical cancer undergoing chemoradiation.
Detailed description
External beam radiation therapy (EBRT) with concurrent chemotherapy followed by brachytherapy is a highly effective treatment for locally advanced cervical cancer (LACC). However, treatment-related toxicity is common and reduces the patient's quality of life (QoL) and may affect ability to complete treatment or undergo adjuvant therapies. Intensity modulated proton therapy (IMPT) enables a significant dose reduction in organs at risk (OAR), when compared to that of standard intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT). However, clinical studies evaluating whether IMPT consequently reduces side effects for LACC are lacking. The PROTECT trial is a nonrandomized prospective multicenter phase-II-trial comparing clinical outcomes after IMPT or IMRT/VMAT in LACC. Thirty women aged \>18 years with a histological diagnosis of LACC will be included in either the IMPT or IMRT/VMAT group. Treatment includes EBRT (45 Gy in 25 fractions of 1.8 Gy), concurrent five weekly cisplatin (40 mg/m2), and 3D image (MRI)-guided adaptive brachytherapy. The primary endpoint is pelvic bones Dmean and mean bowel V15Gy. Secondary endpoints include dosimetric parameters, oncological outcomes, health-related QoL, immune response, safety, and tolerability. This study provides the first data on the potential of IMPT to reduce OAR dose in clinical practice and improve toxicity and QoL for patients with LACC.
Interventions
RADIATIONExternal beam radiation therapy: IMRT/VMAT
EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
RADIATIONExternal beam radiation therapy: IMPT
EBRT is given to a total dose of 45 Gy in 25 daily fractions of 1.8 Gy in 5 weeks. Involved nodes are boosted using a simultaneous integrated boost (SIB) to reach a total EBRT plus brachytherapy dose of 60 Gy EQD2 to provide high nodal control.
DRUGCisplatin
The standard chemotherapy regimen is weekly cisplatin (40 mg/m2) for 5 weeks.
RADIATIONBrachytherapy
Brachytherapy is performed using a high-dose rate (HDR) after loading system to deliver a boost to any residual tumor and the cervix. Brachytherapy dose is (21-) 28 Gy in fractions of 7 Gy specified at 100% isodose around the high-risk CTV, according to the EMBRACE-II prescription protocol. The aim is to reach an equivalent dose in 2 Gy fractions including EBRT (EQD2\_D90) of the high-risk CTV between 90-95 Gy, using MRI-guided adaptive brachytherapy.
Sponsors
Erasmus Medical Center
HollandPTC
Leiden University Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study is designed as a prospective, multicenter, nonrandomized phase-II-trial. During the first phase of the trial, 15 patients will be enrolled in the IMRT/VMAT treatment group. In the second phase of the trial, 15 patients will be enrolled in the IMPT group.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed diagnosis of cervical cancer (squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma, HPV positive or negative) with an indication for curative treatment with primary chemoradiation with concurrent cisplatin followed by 3D image-guided adaptive brachytherapy. * Indication to include the common iliac region (minimum 5, maximum 8) or the common iliac and para-aortic regions (minimum 7, maximum 10) into the elective clinical target volume of the external beam radiotherapy. * No distant metastasis beyond the para-aortic lymph node chain as determined by diagnostic imaging (CT or PET-CT scan) * Age ≥ 18 years * WHO 0-1 * Adequate systemic organ function: * Creatinine clearance (\> 50 cc/min) * Adequate bone marrow function : white blood cells (WBCs) ≥3.0 x 109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l * Patients must be accessible for treatment and follow-up * Written informed consent according to the local Ethics Committee requirements
Exclusion criteria
* Small cell cancer, melanoma and other rare histological types of the cervix. * History of another primary malignancy that could conceivably be active evaluated by the study physician. Examples of exception include, but are not limited to: * Malignancy treated with curative intent and with no known active disease ≥5 years. * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. * Other severe diseases such as recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias * Previous pelvic or abdominal radiotherapy * History of active primary immunodeficiency * Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[e.g. colitis or Crohn's disease\]) * The use of immunosuppressive drugs at baseline * Contraindications for weekly Cisplatin (or Carboplatin) * Contraindications for the use of MRI
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dmean to the pelvic bones | During treatment | Mean dose to the pelvic bones (Gy). |
| Mean V15Gy to the bowel | During treatment | Mean volume of the bowel (cc) receiving 15Gy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Key dosimetric parameters of the sigmoid | During treatment | Mean volume of the sigmoid (%) receiving greater than or equal to 15, 30, and 40Gy. |
| Key dosimetric parameters of the bowel | During treatment | Mean volume of the bowel (cc) receiving greater than or equal to 30 and 40Gy. |
| Complete response | At Month 3 after end of treatment | Absence of disease in the cervix, uterus, upper vagina, and parametria. |
| Pelvic recurrence-free survival | At Month 12 after end of treatment | The time from start of treatment to the first occurrence of pelvic recurrence. |
| Key dosimetric parameters of the body | During treatment | Mean dose to the body (Gy) and mean volume of the body (cm3) receiving greater than or equal to 10 Gy. |
| Key dosimetric parameters of the pelvic bones | During treatment | Mean volume of the pelvic bones (% or cc) receiving greater than or equal to 10, 20, and 40Gy. |
| Key dosimetric parameter of the kidneys | During treatment | Mean dose to the kidneys (Gy). |
| Key dosimetric parameters of the spinal cord | During treatment | Mean volume of the spinal cord (%) receiving greater than or equal to 15 and 30Gy. |
| Key dosimetric parameters of the bladder | During treatment | Mean volume of the bladder (%) receiving greater than or equal to 15, 30, and 40Gy. |
| Overall survival | At Month 12 after end of treatment | The percentage (%) of included patients who are alive after start of treatment |
| Distant recurrence-free survival | At Month 12 after end of treatment | The time from start of treatment to the first occurrence of distant recurrence. |
| Health-related Quality of Life | At baseline, week 4 of EBRT, end of treatment, and at Month 3, Month 6, Month 9, and Month 12 after end of treatment | For the evaluation of patient reported symptoms and QoL, the European Organization for Research and Treatment of Cancer (EORTC)-core (C-30) questionnaire, the CX24 module for cervical cancer, and six additional questions from EN24 module will be used. |
| Safety and tolerability (toxicity) | At baseline, week 4 of EBRT, end of treatment, and at Month 3, Month 6, Month 9, and Month 12 after end of treatment | Toxicity will be graded according to the NCI-CTCAE version 5.0. |
| The effect on the local immune system (analyzed with the Nanostring PanCancer IO 360 panel) | At baseline and at the first brachytherapy session | Tumor biopsies will be collected for evaluation of the impact of treatment on the local immune response. |
| The effect on the systemic immune system | At baseline, week 4 of treatment, and at Month 1, Month 2, Month 3, and Month 12 after end of treatment | Blood samples will be collected for immune-monitoring. Full blood count, peripheral blood mononuclear cells, leukocyte differentiation, APC quality, T cell reactivity, and immune composition changes will be measured. |
| The effect on bone marrow fat fraction | At baseline, for brachytherapy purposes, and at Month 3 and Month 12 after end of treatment. | Patients will have an MR scan with Dixon technique for evaluation of bone marrow fat fraction in the vertebral column and femoral necks. |
| Other dosimetric parameters of critical organs | During treatment | Mean volume of an organ at risk (% or cc) receiving greater than or equal to xGy. |
| Key dosimetric parameters of the rectum | During treatment | Mean volume of the rectum (%) receiving greater than or equal to 15, 30, and 40Gy. |
Countries
Netherlands
Contacts
Primary ContactAnouk Corbeau, MSc
Backup ContactStephanie M. de Boer, MD, PhD
Outcome results
None listed